Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineHyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine designDNA vaccines: improving expression of antigensStrong purifying selection at synonymous sites in D. melanogasterMultimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.Optimal Induction of T-Cell Responses against Hepatitis C Virus E2 by Antigen Engineering in DNA ImmunizationCo-evolution of a broadly neutralizing HIV-1 antibody and founder virusFine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.Synergistic cooperation between methamphetamine and HIV-1 gsp120 through the P13K/Akt pathway induces IL-6 but not IL-8 expression in astrocytesBroad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolatesMultiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expressionCodon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickensHigh guanine and cytosine content increases mRNA levels in mammalian cellsImmunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skinA Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability.T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizationsVaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunityMultiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidateIntracellular mannose binding lectin mediates subcellular trafficking of HIV-1 gp120 in neuronsCodon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice.Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85BC3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequencesDifferential trends in the codon usage patterns in HIV-1 genesNovel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunityIdentification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesStable expression of primary human immunodeficiency virus type 1 structural gene products by use of a noncytopathic sindbis virus vectorExpression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses.Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.Mass spectrometry approach and ELISA reveal the effect of codon optimization on N-linked glycosylation of HIV-1 gp120Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routesUnique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
P2860
Q21092234-BA40EBEE-A932-4F03-AF3D-096E307636EAQ24679395-E9168E88-BFC6-4A2D-9BC2-5FF3B203E2F9Q24806169-10740ED4-8E6B-417E-80EC-7EA6B45DCCCCQ24810381-34B2074F-A343-4F0E-9077-9A47738493CFQ27472925-5ECDBD6D-5777-4276-A41C-1C50B8875D8FQ27485755-41938DD9-844D-4D5B-BDBD-5CB6D9143B3AQ27644501-67B2638E-FAAB-446B-A414-DF5D26AFD579Q28217208-9936D2BB-5E80-4793-B440-CAABA129B8F7Q28484371-2E78E8D2-91AE-48D0-9E23-7EA1D8A8D276Q28741775-F1B8155D-9175-401E-8C54-824B01925729Q28742249-29983971-01FA-4F3A-986D-7270439AD0A2Q30392246-7DBAA7BB-F823-49C0-A0BB-5D3E91C70020Q33243412-6B231782-F23F-4075-9CDA-3B1649F43155Q33576984-34EF7DC1-A323-4A99-8B01-67D979B48F69Q33698112-BE0B1795-57A7-4DCE-AE46-161AD4DAC7D0Q33698142-9B3EAC07-7059-487E-80DD-78BAB0F4AC36Q33723334-9A3F8968-009D-4BFA-B281-8F3E496660F5Q33804963-BC64F17F-B645-4C52-A563-0B490F61418EQ33814170-97F2B7AF-7A54-4064-AD7D-1A5B204A9035Q33833624-CF09A83B-2D49-47B5-9259-C54C21387C42Q33846454-14021021-7040-42CB-AC07-1467E0CD456AQ33849127-735A9DF7-86D7-4677-B4EB-4F5A68076265Q33883995-D3505843-5DB0-43D2-97E6-DDC1F473457CQ33891505-295B3283-84D3-45F0-BBA5-DCE528A1315EQ33905432-85B054DE-77B8-4019-BC29-0812DDB66DF4Q34009561-386F99D3-2B68-4CAD-854C-CB4B2697B62DQ34033825-AF4396AB-AD71-4C34-87FA-2762500CA911Q34099087-E345F17A-523B-4606-AC1E-E3F0CA7B2333Q34117041-9C655A8C-96CA-4922-B726-5E032CCEF3D4Q34172564-6339E3D5-26C8-4853-9B8D-A444B5D8B048Q34324992-EBFA24A0-CEC3-4ECB-97A3-6D785E2EC44BQ34356433-3106CC5A-078A-4625-94C3-1CC4153C6576Q34363528-7F2D04B2-B260-4179-B000-AB216D0F5BB7Q34363707-1E238DC7-9BCB-427A-BFBF-166F94658D05Q34395523-DB2DC453-9050-40B9-8A5E-0C15C7C31ED4Q34402934-734FF50F-E1D8-487C-8DE2-87DCCD2053AAQ34545765-01E1F2CA-F092-463B-B6C8-347DA774C283Q34669472-2954641D-9B59-4D39-ACA6-BC8854150F9AQ34983688-63A484E8-F9E0-4F59-9A28-32154888AEB8Q34999724-F9E1EEC4-8D5A-4A76-AD17-6677185BCEE7
P2860
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Increased immune response elic ...... nce with optimized codon usage
@ast
Increased immune response elic ...... nce with optimized codon usage
@en
Increased immune response elic ...... nce with optimized codon usage
@en-gb
Increased immune response elic ...... nce with optimized codon usage
@nl
type
label
Increased immune response elic ...... nce with optimized codon usage
@ast
Increased immune response elic ...... nce with optimized codon usage
@en
Increased immune response elic ...... nce with optimized codon usage
@en-gb
Increased immune response elic ...... nce with optimized codon usage
@nl
prefLabel
Increased immune response elic ...... nce with optimized codon usage
@ast
Increased immune response elic ...... nce with optimized codon usage
@en
Increased immune response elic ...... nce with optimized codon usage
@en-gb
Increased immune response elic ...... nce with optimized codon usage
@nl
P2093
P2860
P3181
P1433
P1476
Increased immune response elic ...... nce with optimized codon usage
@en
P2093
P2860
P304
P3181
P407
P577
1998-02-01T00:00:00Z